Negative in Ames, in vitro human lymphocyte micronucleus and in vivo mouse micronucleus assays
“Daraxonrasib was not mutagenic in the GLP in vitro Ames assay, not clastogenic in the GLP in vitro micronucleus assay with human peripheral blood lymphocytes, and not genotoxic in the GLP in vivo micronucleus study in mice.”
✓ VerifiedFDA multi-discipline review, p. 34Source ↗
Carcinogenicity
Not conducted (advanced cancer indication, ICH S9)
“Carcinogenicity studies were not conducted with daraxonrasib, consistent with ICH S9 recommendations for advanced cancer indications.”
✓ VerifiedFDA multi-discipline review, p. 34Source ↗
Instead of carcinogenicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
Mouse EFD: embryo-fetal toxicity at ≥50 mg/kg/day (2.5x clinical exposure by AUC)
“In an embryo-fetal development study in mice (25, 50, and 75 mg/kg/day), daraxonrasib caused embryo-fetal toxicity at ≥50 mg/kg/day (2.5x exposure at the recommended dose based on AUC).”
✓ VerifiedFDA multi-discipline review, p. 34Source ↗
Safety pharmacology
Monkey CV study: decreased heart rate, prolonged QT, shortened QTc and increased blood pressure at all doses (3, 10, 30 mg/kg)
“In a standalone good laboratory practice (GLP) cardiovascular study in monkey, daraxonrasib demonstrated decreased heart rate, prolonged QT, shortened QTc (secondary to heart rate decrease), and increased blood pressure at all dose levels tested (3, 10, and 30 mg/kg).”
✓ VerifiedFDA multi-discipline review, p. 33Source ↗
Genotox: Ames
Negative
“Daraxonrasib was not mutagenic in an in vitro bacterial reverse mutation (Ames) assay, not clastogenic in an in vitro micronucleus assay in human peripheral blood lymphocytes, and not genotoxic in an in vivo mouse bone marrow micronuclei test.”
In vitro micronucleus (human peripheral blood lymphocytes): negative
“Daraxonrasib was not mutagenic in an in vitro bacterial reverse mutation (Ames) assay, not clastogenic in an in vitro micronucleus assay in human peripheral blood lymphocytes, and not genotoxic in an in vivo mouse bone marrow micronuclei test.”
“Daraxonrasib was not mutagenic in an in vitro bacterial reverse mutation (Ames) assay, not clastogenic in an in vitro micronucleus assay in human peripheral blood lymphocytes, and not genotoxic in an in vivo mouse bone marrow micronuclei test.”
“Carcinogenicity studies were not conducted with daraxonrasib, consistent with ICH S9 recommendations for advanced cancer indications.”
✓ VerifiedFDA multi-discipline review, p. 34Source ↗
Carcinogenicity timing
Not required (ICH S9)
“FDA concurs. Carcinogenicity studies were not required for this Application per ICH S9.”
✓ VerifiedFDA multi-discipline review, p. 200Source ↗
hERG / QT
hERG inhibition 13.3% at 0.8 µM and 36.0% at 2.7 µM; IC50 >2.7 µM
“daraxonrasib inhibited hERG current by 13.3% at 0.8 µM and 36.0% at 2.7 µM versus 0.4% in vehicle control. The IC50 for the inhibitory effect of daraxonrasib on hERG potassium current was not calculated but was estimated to be greater than 2.7 µM.”
✓ VerifiedFDA multi-discipline review, p. 41Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative